In Wednesday’s Wall Street session, Medtronic Plc (NYSE:MDT) shares traded at $88.28, down -0.53% from the previous session.
MDT stock price is now 3.68% away from the 50-day moving average and 1.37% away from the 200-day moving average. The market capitalization of the company currently stands at $113.11B.
On June 16, 2025, Leerink Partners recently initiated its ‘Outperform’ rating on the stock quoting a target price of $110, while ‘Citigroup’ rates the stock as ‘Buy’
In other news, Salmon Sean, Officer bought 18,378 shares of the company’s stock on Jun 06 ’25. The stock was bought for $1,595,469 at an average price of $86.81. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 24 ’25, EVP & Pres Neuroscience Wall Brett A. sold 12,437 shares of the business’s stock. A total of $1,119,330 was realized by selling the stock at an average price of $90.00. This leaves the insider owning 40,979 shares of the company worth $3.62 million. A total of 0.17% of the company’s stock is owned by insiders.
During the past 12 months, Medtronic Plc has had a low of $75.96 and a high of $96.25. As of last week, the company has a debt-to-equity ratio of 0.62, a current ratio of 1.85, and a quick ratio of 1.42. According to the stock market information, the enterprise value for the company is $132580843520, which is based on a 24.40 price-to-earnings ratio, a 4.40 price-to-earnings-growth ratio, and a beta of 0.81. The fifty day moving average price for MDT is $85.1482 and a two-hundred day moving average price translates $87.0889 for the stock.
The latest earnings results from Medtronic Plc (NYSE: MDT) was released for 2025-04-25. The net profit margin was 13.90% and return on equity was 9.49% for MDT. The company reported revenue of $8.93 billion for the quarter, compared to $8.59 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 3.94 percent.
